Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 240 results
Author Title Type [ Year(Desc)]
Filters: First Letter Of Last Name is E  [Clear All Filters]
2021
Wang H, Xu M, Engelhart CA, Zhang X, Yan B, Pan M, Xu Y, Fan S, Liu R, Xu L et al..  2021.  Rediscovery of PF-3845 as a new chemical scaffold inhibiting phenylalanyl-tRNA synthetase in Mycobacterium tuberculosis.. J Biol Chem. 296:100257.
Wang R, Ehrt S.  2021.  Rv0954 Is a Member of the Mycobacterial Cell Division Complex.. Front Microbiol. 12:626461.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..  2021.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..  2021.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..  2021.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Grover S, Engelhart CA, Pérez-Herrán E, Li W, Abrahams KA, Papavinasasundaram K, Bean JM, Sassetti CM, Mendoza-Losana A, Besra GS et al..  2021.  Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis.. ACS Infect Dis. 7(1):141-152.
2022
Heydarchi B, Fong DS, Gao H, Salazar-Quiroz NA, Edwards JM, Gonelli CA, Grimley S, Aktepe TE, Mackenzie C, Wales WJ et al..  2022.  Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody.. Cell Rep Med. 3(5):100635.
Koh E-I, Oluoch PO, Ruecker N, Proulx MK, Soni V, Murphy KC, Papavinasasundaram K, Reames CJ, Trujillo C, Zaveri A et al..  2022.  Chemical-genetic interaction mapping links carbon metabolism and cell wall structure to tuberculosis drug efficacy.. Proc Natl Acad Sci U S A. 119(15):e2201632119.
Kreutzfeldt KM, Jansen RS, Hartman TE, Gouzy A, Wang R, Krieger IV, Zimmerman MD, Gengenbacher M, Sarathy JP, Xie M et al..  2022.  CinA mediates multidrug tolerance in Mycobacterium tuberculosis.. Nat Commun. 13(1):2203.
Li S, Poulton NC, Chang JS, Azadian ZA, DeJesus MA, Ruecker N, Zimmerman MD, Eckartt KA, Bosch B, Engelhart CA et al..  2022.  CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis.. Nat Microbiol. 7(6):766-779.
Li S, Poulton NC, Chang JS, Azadian ZA, DeJesus MA, Ruecker N, Zimmerman MD, Eckartt KA, Bosch B, Engelhart CA et al..  2022.  CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis.. Nat Microbiol. 7(6):766-779.
Smith CM, Baker RE, Proulx MK, Mishra BB, Long JE, Park SWoong, Lee H-N, Kiritsy MC, Bellerose MM, Olive AJ et al..  2022.  Host-pathogen genetic interactions underlie tuberculosis susceptibility in genetically diverse mice.. Elife. 11
Lyu M, Suzuki H, Kang L, Gaspal F, Zhou W, Goc J, Zhou L, Zhou J, Zhang W, Shen Z et al..  2022.  ILC3s select microbiota-specific regulatory T cells to establish tolerance in the gut.. Nature. 610(7933):744-751.
Green SR, Davis SH, Damerow S, Engelhart CA, Mathieson M, Baragaña B, Robinson DA, Tamjar J, Dawson A, Tamaki FK et al..  2022.  Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs.. Nat Commun. 13(1):5992.
Green SR, Davis SH, Damerow S, Engelhart CA, Mathieson M, Baragaña B, Robinson DA, Tamjar J, Dawson A, Tamaki FK et al..  2022.  Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs.. Nat Commun. 13(1):5992.
Green SR, Davis SH, Damerow S, Engelhart CA, Mathieson M, Baragaña B, Robinson DA, Tamjar J, Dawson A, Tamaki FK et al..  2022.  Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs.. Nat Commun. 13(1):5992.
Wilson C, Ray P, Zuccotto F, Hernandez J, Aggarwal A, Mackenzie C, Caldwell N, Taylor M, Huggett M, Mathieson M et al..  2022.  Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target.. J Med Chem. 65(1):409-423.
Wilson C, Ray P, Zuccotto F, Hernandez J, Aggarwal A, Mackenzie C, Caldwell N, Taylor M, Huggett M, Mathieson M et al..  2022.  Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target.. J Med Chem. 65(1):409-423.
Wilson C, Ray P, Zuccotto F, Hernandez J, Aggarwal A, Mackenzie C, Caldwell N, Taylor M, Huggett M, Mathieson M et al..  2022.  Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target.. J Med Chem. 65(1):409-423.
Zhang L, Kent JE, Whitaker M, Young DC, Herrmann D, Aleshin AE, Ko Y-H, Cingolani G, Saad JS, D Moody B et al..  2022.  A periplasmic cinched protein is required for siderophore secretion and virulence of Mycobacterium tuberculosis.. Nat Commun. 13(1):2255.
Laurent P, Yang C, Rendeiro AF, Nilsson-Payant BE, Carrau L, Chandar V, Bram Y, tenOever BR, Elemento O, Ivashkiv LB et al..  2022.  Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19.. Sci Immunol. 7(75):eadd4906.
Govender P, Müller R, Singh K, Reddy V, Eyermann CJ, Fienberg S, Ghorpade SR, Koekemoer L, Myrick A, Schnappinger D et al..  2022.  Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.. J Med Chem. 65(9):6903-6925.
Govender P, Müller R, Singh K, Reddy V, Eyermann CJ, Fienberg S, Ghorpade SR, Koekemoer L, Myrick A, Schnappinger D et al..  2022.  Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.. J Med Chem. 65(9):6903-6925.
2023
Wong AI, Beites T, Planck KA, Fieweger RA, Eckartt KA, Li S, Poulton NC, VanderVen BC, Rhee KY, Schnappinger D et al..  2023.  Cyclic AMP is a critical mediator of intrinsic drug resistance and fatty acid metabolism in M. tuberculosis.. Elife. 12
Wong AI, Beites T, Planck KA, Fieweger RA, Eckartt KA, Li S, Poulton NC, VanderVen BC, Rhee KY, Schnappinger D et al..  2023.  Cyclic AMP is a critical mediator of intrinsic drug resistance and fatty acid metabolism in M. tuberculosis.. Elife. 12